跳至主要内容
临床试验/NCT00855647
NCT00855647已完成2 期

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Stanford University2 个研究点 分布在 1 个国家目标入组 99,999 人开始时间: 2003年8月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
99,999
试验地点
2
主要终点
PSA response that achieves a stable nadir over time.

研究概览

简要总结

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved.
  • Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
  • Adult men will be considered.
  • No life expectancy restrictions will apply.
  • Performance Status will not be considered.
  • No requirements for organ or marrow function will be made
  • Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • No prior prostate treatment will be allowed.
  • The use of other concurrent Investigational Agents will not be allowed.
  • No exclusion requirements due to co-morbid disease or incurrent illness.
  • No requirements regarding history of allergic reactions.
  • Pregnancy or nursing patients is not applicable (ie. patients are male).

结局指标

主要结局

PSA response that achieves a stable nadir over time.

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验